ADNI 연구에서 알츠하이머병 및 경도인지장애의 뇌영상 표지자

• 영문명: Neuroimaging Markers for Alzheimer’s Disease and Mild Cognitive Impairment in Alzheimer’s Disease Neuroimaging Initiative (ADNI)
• 발행기관: 대한노인정신의학회
• 저자명: 이준영(Jun-Young Lee)
• 간행물 정보: 『노인정신의학』노인정신의학 제16권 제1호, 13~16쪽, 전체 4쪽
• 주제분류: 의약학 > 정신과학
• 파일형태: PDF
• 발행일자: 2012.06.30

영문 초록

To find the neuroimaging markers which have high validity to diagnose Alzheimer’s disease and to predict conversion of MCI or normal control to AD, I reviewed papers based on Alzheimer’s disease Neuroimaging Initiative (ADNI) which goal is to collect and validate data such as MRI and PET images, cerebral spinal fluid, and blood biomarkersto define the progression of Alzheimer’s disease. Brain imaging markers have the high accuracy to differentiate Alzheimer’s disease from normal aging, but low accuracy to differentiate mild cognitive impairment from normal aging. Hippocampal volume is the most accurate to differentiate Alzheimer’s disease from normal aging in single region of interest analysis. Entorhinal cortical volume is more accurate to differentiate mild cognitive impairment from normal aging. Multi-brain area analysis is more accurate to diagnose Alzheimer’s disease or to predict Alzheimer’s disease conversion than single brain area analysis. Multimodal analysis of FDG PET and MRI can predict dementia conversion in mild cognitive impairment group. Smaller sample size is needed to test the efficacy of dementia drug when using hippocampal or entorhinal cortical volume than using ADAS-cog.

목차

서론

관심영역분석(Region of Interest, ROI)을 이용한 AD 진단 및 AD 진행 예측

전체뇌분석(Whole Brain Analysis)을 이용한 AD 진단 및 AD 진행 예측

FDG PET를 이용한 AD 진단 및 AD 진행 예측

뇌영상표지자와 약물 연구

결론

REFERENCES

키워드

알츠하이머병 경도인지장애 자기공명영상 양전자단층촬영 Alzheimer’s disease Mild cognitive impairment MRI PET ADNI